2026 3rd Mechanobiologically Active Material Innovative Medical Device Demonstration Infrastructure Biological Test Evaluation Certification Support Project (Industrial Innovation Infrastructure Construction)
Save on medical device regulatory costs by receiving direct GLP test evaluation certification reports from the National Institute of Toxicological Sciences instead of cash grants.
- Eligible
- SMEs and mid-sized companies nationwide in the medical device upstream/downstream industries
- Deadline
- 2026.09.01
This project supports SMEs and mid-sized companies in the medical device industry by providing GLP (Acute Systemic Toxicity) test evaluation certification reports. It operates through direct support from the National Institute of Toxicological Sciences rather than cash grants, requiring applicants to submit documents via email.
3-second summary
- Target: Nationwide SMEs and mid-sized companies in medical device industries
- Application Period: Sep 1, 2026 (Tue) until budget exhaustion (First-come, first-served)
- Support Content: Issuance of GLP (Acute Systemic Toxicity) test evaluation certification report (Direct support mode)
- Required Documents: Application form, test plan, consent form, business registration copy, financial statements, etc.
Eligibility checklist
- Nationwide SMEs and mid-sized companies in the medical device upstream/downstream industries
- Excluded if previously supported or selected for similar projects
- Excluded if the business plan is confirmed to be currently commercializing
- Excluded if restricted from government projects or failing to fulfill obligations
- Excluded if the representative is a credit delinquent or debtor in default
- Excluded if the company is suspended, closed, or undergoing such procedures
- Excluded if the business plan or submitted documents are false
Schedule & how to apply
- Application Period: Sep 1, 2026 (Tue) until budget exhaustion (First-come, first-served)
- How to Apply: Email submission (Subject line must start with '[Test Evaluation]')
- Evaluation Process: Selection after eligibility check based on documents (Supplemented date used if documents are incomplete)
Recommended for
- Recommended for CEOs of SMEs and mid-sized companies needing GLP acute systemic toxicity testing for medical device development.
- Suitable for companies preferring direct test evaluation certification services from specialized research institutes over cash grants.
Frequently asked questions
Who is eligible to apply?
This program is for SMEs and mid-sized companies nationwide in the medical device upstream/downstream industries. Details: Nationwide SMEs and mid-sized companies in the medical device upstream/downstream industries; Excluded if previously supported or selected for similar projects; Excluded if the business plan is confirmed to be currently commercializing; Excluded if restricted from government projects or failing to fulfill obligations.
When is the application deadline?
The application deadline is 2026.09.01. Applications are currently closed. Schedules may change — confirm against the official program notice.
How do I apply?
Applications follow the official program notice, which is in Korean. See the source link for the method and receiving office; Beaconoi can prepare an English draft for your review.
Last updated · Source: official program notice
※ Program information is compiled from each institution’s public sources; actual eligibility, amounts and deadlines may change. Always verify against the official notice (in Korean) before applying.